The company guided Q2 2025 revenues to be between $995 million and $1.005 billion, with non-GAAP EPS expected in the range of $1 to $1.03. Full-year revenue guidance was revised to $4.05 billion to $4 ...

Q1 2025 Earnings Conference Call February 5, 2025 4:30 PM ETCompany ParticipantsMike Watts - Corporate Vice President, ...

BTIG analyst Ryan Zimmerman maintained a Hold rating on Hologic (HOLX – Research Report) yesterday. The company’s shares closed yesterday at ...

The company said that its molecular diagnostics revenues rose 7 percent on the strength of its women's health assays and Biotheranostics business.

While reporting its results for the first quarter, Hologic, Inc. (HOLX) revised its outlook for the full year 2025. Looking forward ...

The stock's rise snapped a three-day losing streak.

Medical technology company Hologic (NASDAQ:HOLX) in Q4 CY2024, but sales were flat year on year at $1.02 billion. On the ...

Hologic lowered its fiscal 2025 revenue forecast, citing weakness in sales of its breast health products, sending the company ...

MARLBOROUGH, Mass. (AP) — MARLBOROUGH, Mass. (AP) — Hologic Inc. (HOLX) on Wednesday reported fiscal first-quarter profit of $201 million. On a per-share basis, the Marlborough, Massachusetts-based ...

Learn more about whether Alcon Inc. or Hologic, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Fintel reports that on February 3, 2025, Needham downgraded their outlook for Hologic (NasdaqGS:HOLX) from Buy to Hold.

Hologic (NASDAQ:HOLX – Get Free Report) will likely be issuing its quarterly earnings data after the market closes on ...